
Dr Anna Bibby
BSc, MBChB, PhD
Current positions
Associate Professor in Respiratory Medicine
Bristol Medical School (THS)
Contact
Press and media
Many of our academics speak to the media as experts in their field of research. If you are a journalist, please contact the University’s Media and PR Team:
Research interests
I am a clinical academic, balancing work as a Respiratory Consultant at North Bristol NHS Trust with research at the University of Bristol Medical School. My interests include lung cancer, malignant pleural disease including mesothelioma, and cancer immunotherapy. I am a keen proponent of pragmatic clinical trials and the use of mixed methods research techniques to answer relevant clinical questions and inform practice.
I lead the Lung Cancer Service at North Bristol NHS Trust and sit on the steering committee for the British Lung Foundation Mesothelioma Research Network. I have contributed to several international guidelines, including the European Respiratory Society Taskforce on Malignant Pleural Effusions, the British Thoracic Society Pleural Guideline and the British Thoracic Society Statement on managing pleural services during COVID-19. I am a faculty member of the British Thoracic Society thoracic ultrasound training course and the European Respiratory Society ultrasound and pleural procedure courses. Recently I have been invited to join the Research Committee of Mesothelioma UK and sit on the advisory board of the newly-established Mesothelioma Applied research Centre in Sheffield.
Publications
Recent publications
28/02/2025201 Understanding public perceptions of lung cancer screening; a qualitative analysis of online responses to news articles
British Thoracic Society Guideline for pleural disease
Thorax
Lymphocyte predominance in blood, pleural fluid, and tumour stroma; a prognostic marker in pleural mesothelioma
BMC Pulmonary Medicine
Ancillary Diagnostic Investigations in Malignant Pleural Mesothelioma
Cancers
Is Systemic Anticancer Therapy Associated With Higher Rates of Malignant Pleural Effusion Control in People With Pharmacologically Sensitive Tumors?
Chest